Income Statement (TTM)
Relief Therapeutics Holding SA Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 5 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 9 | 8 | 6 | 4 |
| Change (%) | 100.00 | 48.81 | 32.80 | -3.67 | -3.81 | -1.80 | -1.83 | 1.46 | 1.44 | 21.20 | 17.49 | -2.03 | -25.92 | -34.99 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 2 | 2 |
| Change (%) | 100.00 | 44.60 | 30.84 | -5.95 | -6.33 | 8.00 | 7.41 | 16.21 | 13.95 | 18.05 | 15.29 | -1.45 | -18.70 | -23.00 | |
| % of Revenue | 22.58 | 22.58 | 21.94 | 21.62 | 21.11 | 20.56 | 22.61 | 24.74 | 28.33 | 31.82 | 31.00 | 30.42 | 30.59 | 33.57 | 39.76 |
| Gross Operating Profit | 1 | 3 | 4 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 5 | 6 | 6 | 4 | 2 |
| Change (%) | 100.00 | 50.04 | 33.35 | -3.04 | -3.14 | -4.34 | -4.53 | -3.39 | -3.51 | 22.67 | 18.48 | -2.28 | -29.10 | -41.04 | |
| % of Revenue | 77.42 | 77.42 | 78.06 | 78.38 | 78.89 | 79.44 | 77.39 | 75.26 | 71.67 | 68.18 | 69.00 | 69.58 | 69.41 | 66.43 | 60.24 |
| SG&A | 12 | 15 | 17 | 19 | 21 | 24 | 25 | 25 | 22 | 19 | 17 | 14 | 10 | 9 | 8 |
| Change (%) | 28.27 | 12.19 | 10.87 | 13.88 | 12.19 | 2.01 | 1.97 | -11.17 | -12.58 | -13.55 | -15.67 | -30.60 | -9.76 | -10.82 | |
| % of Revenue | 710.63 | 455.77 | 343.62 | 286.87 | 339.13 | 395.53 | 410.89 | 426.82 | 373.68 | 322.05 | 229.72 | 164.88 | 116.79 | 142.26 | 195.14 |
| R&D | 21 | 19 | 20 | 21 | 17 | 12 | 8 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Change (%) | -7.21 | 6.12 | 5.77 | -20.98 | -26.55 | -39.15 | -64.34 | -25.31 | -33.88 | -7.53 | -8.14 | 20.30 | -5.64 | -5.97 | |
| % of Revenue | 1,234.66 | 572.84 | 408.52 | 325.37 | 266.90 | 203.80 | 126.28 | 45.87 | 33.77 | 22.01 | 16.79 | 13.13 | 16.12 | 20.54 | 29.70 |
| OpEx | 34 | 38 | 42 | 46 | 43 | 41 | 37 | 32 | 29 | 26 | 23 | 21 | 16 | 14 | 12 |
| Change (%) | 9.23 | 10.83 | 9.77 | -5.09 | -5.36 | -10.20 | -12.03 | -10.48 | -10.81 | -9.77 | -10.83 | -23.00 | -11.92 | -13.53 | |
| % of Revenue | 2,070.73 | 1,130.89 | 842.24 | 696.18 | 685.95 | 674.92 | 617.18 | 553.07 | 487.99 | 429.07 | 319.42 | 242.42 | 190.52 | 226.53 | 301.28 |
| Operating Income | -33 | -34 | -37 | -39 | -37 | -35 | -31 | -27 | -23 | -20 | -16 | -12 | -8 | -8 | -8 |
| Change (%) | 4.62 | 7.14 | 6.67 | -5.32 | -5.62 | -11.66 | -14.00 | -13.11 | -13.97 | -19.19 | -23.74 | -37.73 | 3.55 | 3.43 | |
| % of Revenue | -1,970.73 | -1,030.89 | -742.24 | -596.18 | -585.95 | -574.92 | -517.18 | -453.07 | -387.99 | -329.07 | -219.42 | -142.42 | -90.52 | -126.53 | -201.28 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | 20.50 | 11.34 | 15.28 | -28.31 | -29.41 | -12.70 | -41.82 | -52.34 | -11.48 | 16.67 | 14.29 | 11.11 | -5.00 | -5.26 | |
| % of Revenue | -9.70 | -5.84 | -4.37 | -3.79 | -2.82 | -2.07 | -1.84 | -1.09 | -0.51 | -0.45 | -0.43 | -0.42 | -0.48 | -0.61 | -0.89 |
| Net Income | -33 | -35 | -41 | -47 | -49 | -51 | -66 | -81 | -89 | -98 | -72 | -46 | -17 | -17 | -17 |
| Change (%) | 6.03 | 17.03 | 14.55 | 4.58 | 4.38 | 29.53 | 22.80 | 10.76 | 9.72 | -26.45 | -35.97 | -62.98 | -0.23 | -0.23 | |
| % of Revenue | -1,971.15 | -1,045.02 | -821.85 | -708.93 | -769.67 | -835.22 | -1,101.72 | -1,378.18 | -1,504.58 | -1,627.40 | -987.55 | -538.23 | -203.39 | -273.91 | -420.33 |
Source: Capital IQ
